ライフサイエンスコーパス: NED

1 ated patients (85.2%) ultimately achieved an NED state, and 38 (46.9%) remain continuously NED with m

2 /serotonin products, in CR2-TAg NE cells and NED.

3 e different fluorescent dyes (6FAM, VIC, and NED), demonstrating that it is possible to analyze up to

4 zo-dye formation, abbreviated as "4-ATP-AuNP+NED" colorimetric method.

5 The two-pore channel blocker NED-19 (1 mum) and the nicotinic acid adenine dinucleoti

6 Within complexes, NED proteins have larger interaction interfaces and asse

7 Seven of these 10 are continuously NED and three are currently NED with salvage therapy.

8 15 of these patients (48%) are continuously NED despite no further therapy and five additional patie

9 However, 22 of 41 (53.7%) are continuously NED despite no further therapy.

10 R with initial chemotherapy are continuously NED with VeIP.

11 Overall, 16 of 47 patients have continuously NED, an additional four patients have NED with further t

12 sease at presentation, two have continuously NED.

13 STMs at time of resection have continuously NED.

14 nt chemotherapy, and seven have continuously NED.

15 isease at presentation, 14 have continuously NED.

16 Five of these patients remain continuously NED after chemotherapy alone, including three who were c

17 ED state, and 38 (46.9%) remain continuously NED with median follow-up from LR therapy of 24.5 months

18 otherapy surgery, and 12 remain continuously NED.

19 ee (NED), and 20 (46.5%) remain continuously NED.

20 ), whereas nine other patients are currently NED after therapy for subsequent relapses.

21 five additional patients (16%) are currently NED with salvage therapy.

22 ht additional patients (19.5%) are currently NED with salvage therapy.

23 are continuously NED and three are currently NED with salvage therapy.

24 One additional CR is currently NED more than 63 months after paclitaxel plus gemcitabin

25 nts have NED with further therapy (currently NED), two patients are alive with disease, 23 patients d

26 Many non-exponentially degraded (NED) proteins are subunits of complexes that are produce

27 ticles (AuNPs) and naphthylethylene diamine (NED) as coupling agent for azo-dye formation, abbreviate

28 Neuroendocrine differentiation (NED) in adenocarcinoma of the human prostate (CaP) is as

29 mice display neuroendocrine differentiation (NED), but NE cancer does not develop.

30 etween patients with no evidence of disease (NED) after radiation and those who had persistent or rec

31 ts continuously show no evidence of disease (NED) and eight additional patients (19.5%) are currently

32 (20%) patients have no evidence of disease (NED) at a median follow-up of 39 months (32-65 months).

33 who continuously had no evidence of disease (NED) were as follows: group A, 92%; group B, 40%; group

34 ients currently have no evidence of disease (NED), and four patients died of disease.

35 ts continuously have no evidence of disease (NED).

36 Amplifying genes encoding NED proteins increases their initial degradation.

37 t population) are continuously disease free (NED) with paclitaxel plus gemcitabine alone (no postchem

38 nderwent surgery were rendered disease free (NED), and 20 (46.5%) remain continuously NED.

39 dditional patient was rendered disease-free (NED) with the resection of residual carcinoma.

40 All five patients currently have NED.

41 uously NED, an additional four patients have NED with further therapy (currently NED), two patients a

42 and (naphthyl)ethylenediamine hydrochloride (NED) with nitrite in acidic medium, yielding a coloured

43 biting apoptosis and activating autophagy in NED PCa cells.

44 a (ED donors, n=589) and those that did not (NED donors, n=703).

45 ) in normal and CR2-TAg NE cells and foci of NED in human CaP, (b) glutamic acid decarboxylase and it

46 MAOA inhibitors significantly reduced NED and autophagy activation of PCa cells.

47 these 32 patients were successfully rendered NED by postchemotherapy surgery, and 12 remain continuou

48 Following recent reports showing that NED of PCa requires down-regulation of repressor element

49 direct costs were significantly lower in the NED donors ($29,879.4+/-11590.1 vs. $19,019.6+/-7599.60,

50 ransplanted were significantly higher in the NED donors ($8,414.5+/-138.29 vs. $9,272.04+/-344.56, P<

51 transplanted was significantly longer in the NED donors (23.1+/-0.8 hr vs. 36.9+/-3.2 hr, P<0.001).

52 d per donor was significantly shorter in the NED donors (91.2+/-44.9 hr vs. 86.8+/-78.6 hr, P=0.01).

53 plexing using the fluorescent dyes FAM, VIC, NED, and ROX.

54 +/-0.8, P<0.0001) in ED donors compared with NED donors.